

MarÃ-a S Aymerich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2274719/publications.pdf>

Version: 2024-02-01

51
papers

2,310
citations

186265

28
h-index

214800

47
g-index

52
all docs

52
docs citations

52
times ranked

3064
citing authors

#	ARTICLE	IF	CITATIONS
1	Two Functional Epitopes of Pigment Epithelialâ€Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer. <i>Cancer Research</i> , 2005, 65, 5144-5152.	0.9	157
2	Direct involvement of Î²f-1 receptors in the dopamine D ₁ receptor-mediated effects of cocaine. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18676-18681.	7.1	153
3	Effective GDNF brain delivery using microspheresâ€A promising strategy for Parkinson's disease. <i>Journal of Controlled Release</i> , 2009, 135, 119-126.	9.9	131
4	Binding of Pigment Epithelium-derived Factor (PEDF) to Retinoblastoma Cells and Cerebellar Granule Neurons. <i>Journal of Biological Chemistry</i> , 1999, 274, 31605-31612.	3.4	120
5	Expression of the mRNAs encoding for the vesicular glutamate transporters 1 and 2 in the rat thalamus. <i>Journal of Comparative Neurology</i> , 2007, 501, 703-715.	1.6	106
6	Identification of the Neuroprotective Molecular Region of Pigment Epithelium-Derived Factor and Its Binding Sites on Motor Neurons. <i>Journal of Neuroscience</i> , 2002, 22, 9378-9386.	3.6	102
7	Thalamic innervation of the direct and indirect basal ganglia pathways in the rat: Ipsi- and contralateral projections. <i>Journal of Comparative Neurology</i> , 2005, 483, 143-153.	1.6	85
8	Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. <i>European Journal of Neuroscience</i> , 2006, 23, 2099-2108.	2.6	75
9	Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. <i>Biochemical Pharmacology</i> , 2018, 157, 67-84.	4.4	75
10	Striatal expression of GDNF and differential vulnerability of midbrain dopaminergic cells. <i>European Journal of Neuroscience</i> , 2005, 21, 1815-1827.	2.6	74
11	The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. <i>Neurobiology of Aging</i> , 2014, 35, 2603-2616.	3.1	71
12	Thalamic innervation of striatal and subthalamic neurons projecting to the rat entopeduncular nucleus. <i>European Journal of Neuroscience</i> , 2004, 19, 1267-1277.	2.6	67
13	GPR55: A therapeutic target for Parkinson's disease?. <i>Neuropharmacology</i> , 2017, 125, 319-332.	4.1	67
14	Interactions between Calmodulin, Adenosine A2A, and Dopamine D2 Receptors. <i>Journal of Biological Chemistry</i> , 2009, 284, 28058-28068.	3.4	65
15	Evidence for pigment epithelium-derived factor receptors in the neural retina. <i>Investigative Ophthalmology and Visual Science</i> , 2001, 42, 3287-93.	3.3	64
16	Structures for G-Protein-Coupled Receptor Tetramers in Complex with G Proteins. <i>Trends in Biochemical Sciences</i> , 2015, 40, 548-551.	7.5	60
17	Gut microbial dysbiosis after traumatic brain injury modulates the immune response and impairs neurogenesis. <i>Acta Neuropathologica Communications</i> , 2021, 9, 40.	5.2	55
18	Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinsonâ€™s disease. <i>Brain, Behavior, and Immunity</i> , 2016, 57, 94-105.	4.1	51

#	ARTICLE	IF	CITATIONS
19	Sustained release of bioactive glycosylated glial cell-line derived neurotrophic factor from biodegradable polymeric microspheres. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008, 69, 844-851.	4.3	50
20	Pharmacologic antagonism of dopamine receptor D3 attenuates neurodegeneration and motor impairment in a mouse model of Parkinson's disease. <i>Neuropharmacology</i> , 2017, 113, 110-123.	4.1	49
21	Expression of vesicular glutamate transporters 1 and 2 in the cells of origin of the rat thalamostriatal pathway. <i>Journal of Chemical Neuroanatomy</i> , 2008, 35, 101-107.	2.1	47
22	GPR40 activation leads to CREB and ERK phosphorylation in primary cultures of neurons from the mouse CNS and in human neuroblastoma cells. <i>Hippocampus</i> , 2014, 24, 733-739.	1.9	46
23	Detection of two different mRNAs in a single section by dual in situ hybridization: A comparison between colorimetric and fluorescent detection. <i>Journal of Neuroscience Methods</i> , 2007, 162, 119-128.	2.5	44
24	Long-term neuroprotection and neurorestoration by glial cell-derived neurotrophic factor microspheres for the treatment of Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1943-1947.	3.9	39
25	Monocyte Inducible Nitric Oxide Synthase in Multiple Sclerosis: Regulatory Role of Nitric Oxide. <i>Nitric Oxide - Biology and Chemistry</i> , 1997, 1, 95-104.	2.7	38
26	Dopamine Receptor D3 Expression Is Altered in CD4+ T-Cells From Parkinson's Disease Patients and Its Pharmacologic Inhibition Attenuates the Motor Impairment in a Mouse Model. <i>Frontiers in Immunology</i> , 2019, 10, 981.	4.8	36
27	Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors. <i>Molecular Neurobiology</i> , 2016, 53, 2312-2319.	4.0	32
28	Stereological Estimates of Glutamatergic, GABAergic, and Cholinergic Neurons in the Pedunculopontine and Laterodorsal Tegmental Nuclei in the Rat. <i>Frontiers in Neuroanatomy</i> , 2018, 12, 34.	1.7	31
29	Midbrain microglia mediate a specific immunosuppressive response under inflammatory conditions. <i>Journal of Neuroinflammation</i> , 2019, 16, 233.	7.2	31
30	Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks. <i>Neuroscience and Biobehavioral Reviews</i> , 2017, 76, 380-395.	6.1	28
31	Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. <i>American Journal of Clinical Pathology</i> , 2000, 114, 786-792.	0.7	25
32	Calcium-mediated modulation of the quaternary structure and function of adenosine A2A-dopamine D2 receptor heteromers. <i>Current Opinion in Pharmacology</i> , 2010, 10, 67-72.	3.5	25
33	The search for a role of the caudal intralaminar nuclei in the pathophysiology of Parkinson's disease. <i>Brain Research Bulletin</i> , 2009, 78, 55-59.	3.0	24
34	Purification of bioactive glycosylated recombinant glial cell line-derived neurotrophic factor. <i>International Journal of Pharmaceutics</i> , 2007, 344, 9-15.	5.2	21
35	The expression of cannabinoid type 1 receptor and 2-arachidonoyl glycerol synthesizing/degrading enzymes is altered in basal ganglia during the active phase of levodopa-induced dyskinesia. <i>Neurobiology of Disease</i> , 2018, 118, 64-75.	4.4	20
36	Inducible Nitric Oxide Synthase in Monocytes from Patients with Graves' Disease. <i>Biochemical and Biophysical Research Communications</i> , 1996, 226, 723-729.	2.1	19

#	ARTICLE	IF	CITATIONS
37	Inducible Nitric Oxide Synthase (iNOS) Expression in Human Monocytes Triggered by \hat{I}^2 -Endorphin through an Increase in cAMP. <i>Biochemical and Biophysical Research Communications</i> , 1998, 245, 717-721.	2.1	18
38	Loss of Parvalbumin-Positive Neurons From the Globus Pallidus in Animal Models of Parkinson Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 973-982.	1.7	16
39	â€Functionalâ€™™ neuroanatomical tract tracing: Analysis of changes in gene expression of brain circuits of interest. <i>Brain Research</i> , 2006, 1072, 91-98.	2.2	12
40	Two-color Fluorescence Labeling in Acrolein-fixed Brain Tissue. <i>Journal of Histochemistry and Cytochemistry</i> , 2010, 58, 359-368.	2.5	11
41	Understanding the Potential Role of Sirtuin 2 on Aging: Consequences of SIRT2.3 Overexpression in Senescence. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3107.	4.1	11
42	Expression of Endothelial NOX5 Alters the Integrity of the Blood-Brain Barrier and Causes Loss of Memory in Aging Mice. <i>Antioxidants</i> , 2021, 10, 1311.	5.1	11
43	Production of highly pure human glycosylated GDNF in a mammalian cell line. <i>International Journal of Pharmaceutics</i> , 2010, 385, 6-11.	5.2	10
44	A simple and efficient method for the production of human glycosylated glial cell line-derived neurotrophic factor using a Semliki Forest virus expression system. <i>International Journal of Pharmaceutics</i> , 2013, 440, 19-26.	5.2	9
45	CB2 Receptors and Neuronâ€™Glial Interactions Modulate Neurotoxicity Generated by MAGL Inhibition. <i>Biomolecules</i> , 2020, 10, 1198.	4.0	9
46	Cocaine selfâ€™administration markedly increases dopamine D₂ receptor negative cooperativity for dopamine binding: A receptor dimerâ€™based analysis. <i>Synapse</i> , 2010, 64, 566-569.	1.2	8
47	Impact of Neurodegenerative Diseases on Drug Binding to Brain Tissues: From Animal Models to Human Samples. <i>Neurotherapeutics</i> , 2018, 15, 742-750.	4.4	5
48	Real-Time G-Protein-Coupled Receptor Imaging to Understand and Quantify Receptor Dynamics. <i>Scientific World Journal</i> , The, 2011, 11, 1995-2010.	2.1	2
49	Intralaminar Thalamic Nuclei are Main Regulators of Basal Ganglia. , 2005, , 331-339.		2
50	Cannabinoid receptor type 2 as a therapeutic target for Parkinson's disease. , 2020, , 557-573.		2
51	Characterization and Localization of Pigment Epithelium-Derived Factor Binding Sites in the Bovine Retina. , 2001, , 127-133.		0